{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T02:50:23Z","timestamp":1793155823661,"version":"4.5.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T00:00:00Z","timestamp":1737504000000},"content-version":"vor","delay-in-days":21,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s13555-024-01323-9","type":"journal-article","created":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T12:17:44Z","timestamp":1737548264000},"page":"161-188","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Long-Term Safety of Ixekizumab Treatment in Patients with Psoriasis, Psoriatic Arthritis, or Axial Spondyloarthritis: a Post\u00a0Hoc Analysis of Cerebro-Cardiovascular Events"],"prefix":"10.1007","volume":"15","author":[{"given":"Mark","family":"Lebwohl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atul","family":"Deodhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Schwartzman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Salvarani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan","family":"Feely McDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Bello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsie L.","family":"Grace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsa","family":"Inman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andris","family":"Kronbergs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Ngantcha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Proton","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim A.","family":"Papp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph F.","family":"Merola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice B.","family":"Gottlieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Blauvelt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,22]]},"reference":[{"issue":"10","key":"1323_CR1","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2023.103410","volume":"22","author":"G Monteleone","year":"2023","unstructured":"Monteleone G, Moscardelli A, Colella A, Marafini I, Salvatori S. Immune-mediated inflammatory diseases: common and different pathogenic and clinical features. Autoimmun Rev. 2023;22(10): 103410.","journal-title":"Autoimmun Rev"},{"issue":"4","key":"1323_CR2","first-page":"612","volume":"31","author":"C Papagoras","year":"2013","unstructured":"Papagoras C, Voulgari PV, Drosos A. Atherosclerosis and cardiovascular disease in the spondyloarthritides, particularly ankylosing spondylitis and psoriatic arthritis. Clin Exp Rheumatol. 2013;31(4):612\u201320.","journal-title":"Clin Exp Rheumatol"},{"issue":"11","key":"1323_CR3","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s11883-021-00963-y","volume":"23","author":"B Weber","year":"2021","unstructured":"Weber B, Merola JF, Husni ME, Di Carli M, Berger JS, Garshick MS. Psoriasis and cardiovascular disease: novel mechanisms and evolving therapeutics. Curr Atheroscler Rep. 2021;23(11):67.","journal-title":"Curr Atheroscler Rep"},{"key":"1323_CR4","volume":"8","author":"E Toussirot","year":"2021","unstructured":"Toussirot E. The risk of cardiovascular diseases in axial spondyloarthritis. Current insights. Front Med (Lausanne). 2021;8:782150.","journal-title":"Front Med (Lausanne)"},{"issue":"8","key":"1323_CR5","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.amjmed.2011.03.028","volume":"124","author":"NN Mehta","year":"2011","unstructured":"Mehta NN, Yu Y, Pinnelas R, et al. Attributable risk estimate of severe psoriasis on major cardiovascular events. Am J Med. 2011;124(8):775 (e1\u2013e6).","journal-title":"Am J Med"},{"issue":"2","key":"1323_CR6","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1136\/annrheumdis-2014-205675","volume":"74","author":"A Ogdie","year":"2015","unstructured":"Ogdie A, Yu Y, Haynes K, et al. Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study. Ann Rheum Dis. 2015;74(2):326\u201332.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"1323_CR7","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1111\/j.1365-2133.2008.08707.x","volume":"159","author":"J Kaye","year":"2008","unstructured":"Kaye J, Li L, Jick S. Incidence of risk factors for myocardial infarction and other vascular diseases in patients with psoriasis. Br J Dermatol. 2008;159(4):895\u2013902.","journal-title":"Br J Dermatol"},{"issue":"4","key":"1323_CR8","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1001\/archdermatol.2009.48","volume":"145","author":"AA Qureshi","year":"2009","unstructured":"Qureshi AA, Choi HK, Setty AR, Curhan GC. Psoriasis and the risk of diabetes and hypertension: a prospective study of US female nurses. Arch Dermatol. 2009;145(4):379\u201382.","journal-title":"Arch Dermatol"},{"issue":"8","key":"1323_CR9","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/s41584-019-0256-0","volume":"15","author":"LD Ferguson","year":"2019","unstructured":"Ferguson LD, Siebert S, McInnes IB, Sattar N. Cardiometabolic comorbidities in RA and PsA: lessons learned and future directions. Nat Rev Rheumatol. 2019;15(8):461\u201374.","journal-title":"Nat Rev Rheumatol"},{"issue":"21_suppl_1","key":"1323_CR10","doi-asserted-by":"crossref","first-page":"II-2","DOI":"10.1161\/01.CIR.0000129535.04194.38","volume":"109","author":"JT Willerson","year":"2004","unstructured":"Willerson JT, Ridker PM. Inflammation as a cardiovascular risk factor. Circulation. 2004;109(21_suppl_1):II-2\u2013II\u221210.","journal-title":"Circulation"},{"issue":"4","key":"1323_CR11","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.jaad.2017.06.028","volume":"77","author":"A Egeberg","year":"2017","unstructured":"Egeberg A, Skov L, Joshi AA, et al. The relationship between duration of psoriasis, vascular inflammation, and cardiovascular events. J Am Acad Dermatol. 2017;77(4):650\u20136 (e3).","journal-title":"J Am Acad Dermatol"},{"issue":"17","key":"1323_CR12","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.3390\/jcm12175446","volume":"12","author":"I Al-Zakwani","year":"2023","unstructured":"Al-Zakwani I, Al-Maqbali JS, AlMahmeed W, AlRawahi N, Al-Asmi A, Zubaid M. Association between non-steroidal anti-inflammatory drug use and major cardiovascular outcomes in patients with acute coronary syndrome in the Arabian Gulf. J Clin Med. 2023;12(17):5446.","journal-title":"J Clin Med"},{"issue":"10","key":"1323_CR13","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1038\/jid.2013.149","volume":"133","author":"EJ Samarasekera","year":"2013","unstructured":"Samarasekera EJ, Neilson JM, Warren RB, Parnham J, Smith CH. Incidence of cardiovascular disease in individuals with psoriasis: a systematic review and meta-analysis. J Investig Dermatol. 2013;133(10):2340\u20136.","journal-title":"J Investig Dermatol"},{"issue":"1","key":"1323_CR14","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1136\/annrheumdis-2014-206147","volume":"75","author":"I Essers","year":"2016","unstructured":"Essers I, Stolwijk C, Boonen A, et al. Ankylosing spondylitis and risk of ischaemic heart disease: a population-based cohort study. Ann Rheum Dis. 2016;75(1):203\u20139.","journal-title":"Ann Rheum Dis"},{"key":"1323_CR15","volume":"369","author":"R Parisi","year":"2020","unstructured":"Parisi R, Iskandar IYK, Kontopantelis E, et al. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ. 2020;369:m1590.","journal-title":"BMJ"},{"key":"1323_CR16","volume":"7","author":"T Torres","year":"2020","unstructured":"Torres T, Barcelos A, Filipe P, Fonseca JE. A systematic review with network meta-analysis of the available biologic therapies for psoriatic disease domains. Front Med (Lausanne). 2020;7:618163.","journal-title":"Front Med (Lausanne)"},{"issue":"6","key":"1323_CR17","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1080\/14712598.2018.1468884","volume":"18","author":"A Jones","year":"2018","unstructured":"Jones A, Ciurtin C, Ismajli M, Leandro M, Sengupta R, Machado PM. Biologics for treating axial spondyloarthritis. Expert Opin Biol Ther. 2018;18(6):641\u201352.","journal-title":"Expert Opin Biol Ther"},{"key":"1323_CR18","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.3389\/fimmu.2019.03096","volume":"10","author":"E von Stebut","year":"2019","unstructured":"von Stebut E, Boehncke WH, Ghoreschi K, et al. IL-17A in psoriasis and beyond: cardiovascular and metabolic implications. Front Immunol. 2019;10:3096.","journal-title":"Front Immunol"},{"issue":"1","key":"1323_CR19","volume":"19","author":"JMG Ruiz de Morales","year":"2020","unstructured":"Ruiz de Morales JMG, Puig L, Daud\u00e9n E, et al. Critical role of interleukin (IL)-17 in inflammatory and immune disorders: an updated review of the evidence focusing in controversies. Autoimmun Rev. 2020;19(1):102429.","journal-title":"Autoimmun Rev"},{"issue":"9","key":"1323_CR20","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.120.011199","volume":"13","author":"H Choi","year":"2020","unstructured":"Choi H, Uceda DE, Dey AK, et al. Treatment of psoriasis with biologic therapy is associated with improvement of coronary artery plaque lipid-rich necrotic core: results from a prospective, observational study. Circ Cardiovasc Imaging. 2020;13(9):e011199.","journal-title":"Circ Cardiovasc Imaging"},{"issue":"10","key":"1323_CR21","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1016\/j.jid.2021.03.024","volume":"141","author":"A Gonz\u00e1lez-Cantero","year":"2021","unstructured":"Gonz\u00e1lez-Cantero A, Ortega-Quijano D, \u00c1lvarez-D\u00edaz N, et al. Impact of biological agents on imaging and biomarkers of cardiovascular disease in patients with psoriasis: a systematic review and meta-analysis of randomized placebo-controlled trials. J Investig Dermatol. 2021;141(10):2402\u201311.","journal-title":"J Investig Dermatol"},{"issue":"4","key":"1323_CR22","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1111\/bjd.14964","volume":"176","author":"W Rungapiromnan","year":"2017","unstructured":"Rungapiromnan W, Yiu Z, Warren R, Griffiths C, Ashcroft D. Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta-analysis of randomized controlled trials. Br J Dermatol. 2017;176(4):890\u2013901.","journal-title":"Br J Dermatol"},{"issue":"10","key":"1323_CR23","first-page":"1002","volume":"16","author":"R Bissonnette","year":"2017","unstructured":"Bissonnette R, Kerdel F, Naldi L, et al. Evaluation of risk of major adverse cardiovascular events with biologic therapy in patients with psoriasis. J Drugs Dermatol. 2017;16(10):1002\u201313.","journal-title":"J Drugs Dermatol"},{"issue":"5","key":"1323_CR24","volume":"16","author":"R Ni","year":"2024","unstructured":"Ni R, Zheng J, Varghese J, Kumar B. The impact of interleukin-17 inhibitors on major adverse cardiovascular events in psoriasis or psoriatic arthritis patients naive to biologic agents: a systematic review and meta-analysis of randomized controlled trials. Cureus. 2024;16(5):e60980.","journal-title":"Cureus"},{"issue":"4","key":"1323_CR25","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1093\/rheumatology\/keab522","volume":"61","author":"L Pina Vegas","year":"2022","unstructured":"Pina Vegas L, Le Corvoisier P, Penso L, Paul M, Sbidian E, Claudepierre P. Risk of major adverse cardiovascular events in patients initiating biologics\/apremilast for psoriatic arthritis: a nationwide cohort study. Rheumatology (Oxford). 2022;61(4):1589\u201399.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"1323_CR26","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13075-022-02836-4","volume":"24","author":"OC Kwon","year":"2022","unstructured":"Kwon OC, Park MC. Effect of tumor necrosis factor inhibitors on risk of cardiovascular disease in patients with axial spondyloarthritis. Arthritis Res Ther. 2022;24(1):141.","journal-title":"Arthritis Res Ther"},{"key":"1323_CR27","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2147\/JIR.S100940","volume":"9","author":"L Liu","year":"2016","unstructured":"Liu L, Lu J, Allan BW, et al. Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A. J Inflamm Res. 2016;9:39\u201350.","journal-title":"J Inflamm Res"},{"issue":"4","key":"1323_CR28","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1056\/NEJMoa1512711","volume":"375","author":"KB Gordon","year":"2016","unstructured":"Gordon KB, Blauvelt A, Papp KA, et al. Phase\u00a03 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med. 2016;375(4):345\u201356.","journal-title":"N Engl J Med"},{"issue":"3","key":"1323_CR29","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/bjd.16050","volume":"178","author":"KA Papp","year":"2018","unstructured":"Papp KA, Leonardi CL, Blauvelt A, et al. Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3). Br J Dermatol. 2018;178(3):674\u201381.","journal-title":"Br J Dermatol"},{"issue":"10","key":"1323_CR30","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1007\/s10067-022-06218-8","volume":"41","author":"LC Coates","year":"2022","unstructured":"Coates LC, Mease P, Kronbergs A, et al. Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results. Clin Rheumatol. 2022;41(10):3035\u201347.","journal-title":"Clin Rheumatol"},{"issue":"2","key":"1323_CR31","volume":"12","author":"K Reich","year":"2022","unstructured":"Reich K, Kristensen LE, Smith SD, et al. Efficacy and safety of ixekizumab versus adalimumab in biologic-na\u00efve patients with active psoriatic arthritis and moderate-to-severe psoriasis: 52-week results from the randomized SPIRIT-H2H trial. Dermatol Pract Concept. 2022;12(2):e2022104.","journal-title":"Dermatol Pract Concept"},{"issue":"5","key":"1323_CR32","doi-asserted-by":"crossref","first-page":"718","DOI":"10.3899\/jrheum.221022.C1","volume":"50","author":"A Deodhar","year":"2023","unstructured":"Deodhar A, Poddubnyy D, Rahman P, et al. Long-term safety and efficacy of ixekizumab in patients with axial spondyloarthritis: 3-year data from the COAST program. J Rheumatol. 2023;50(5):718.","journal-title":"J Rheumatol"},{"issue":"1","key":"1323_CR33","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jaad.2018.02.074","volume":"79","author":"A Egeberg","year":"2018","unstructured":"Egeberg A, Wu JJ, Korman N, et al. Ixekizumab treatment shows a neutral impact on cardiovascular parameters in patients with moderate-to-severe plaque psoriasis: results from UNCOVER-1, UNCOVER-2, and UNCOVER-3. J Am Acad Dermatol. 2018;79(1):104-9.e8.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1323_CR34","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13075-023-03257-7","volume":"26","author":"A Deodhar","year":"2024","unstructured":"Deodhar A, Blauvelt A, Lebwohl M, et al. Long-term safety of Ixekizumab in adults with psoriasis, psoriatic arthritis, or axial spondyloarthritis: a post-hoc analysis of final safety data from 25 randomized clinical trials. Arthritis Res Ther. 2024;26(1):49.","journal-title":"Arthritis Res Ther"},{"key":"1323_CR35","doi-asserted-by":"crossref","first-page":"1353893","DOI":"10.3389\/fmed.2024.1353893","volume":"11","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Yang Z, Gong J, Shi D. Effects of secukinumab and ixekizumab on major adverse cardiovascular events in patients with psoriasis: a meta-analysis of randomized controlled trials. Front Med (Lausanne). 2024;11:1353893.","journal-title":"Front Med (Lausanne)"},{"issue":"12","key":"1323_CR36","doi-asserted-by":"crossref","first-page":"3834","DOI":"10.1093\/rheumatology\/keaa189","volume":"59","author":"MC Genovese","year":"2020","unstructured":"Genovese MC, Mysler E, Tomita T, et al. Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials. Rheumatology. 2020;59(12):3834\u201344.","journal-title":"Rheumatology"},{"issue":"11","key":"1323_CR37","doi-asserted-by":"crossref","first-page":"5485","DOI":"10.1093\/rheumatology\/keab566","volume":"60","author":"MC Genovese","year":"2021","unstructured":"Genovese MC, Mysler E, Tomita T, et al. Corrigendum to: Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials. Rheumatology. 2021;60(11):5485.","journal-title":"Rheumatology"},{"issue":"1","key":"1323_CR38","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13075-020-2099-0","volume":"22","author":"B Combe","year":"2020","unstructured":"Combe B, Rahman P, Kameda H, et al. Safety results of ixekizumab with 1822.2 patient-years of exposure: an integrated analysis of 3 clinical trials in adult patients with psoriatic arthritis. Arthritis Res Ther. 2020;22(1):14.","journal-title":"Arthritis Res Ther"},{"issue":"10163","key":"1323_CR39","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1016\/S0140-6736(18)31946-9","volume":"392","author":"D van der Heijde","year":"2018","unstructured":"van der Heijde D, Wei JC-C, Dougados M, et al. Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16\u00a0week results of a phase\u00a03 randomised, double-blind, active-controlled and placebo-controlled trial. The Lancet. 2018;392(10163):2441\u201351.","journal-title":"The Lancet"},{"issue":"4","key":"1323_CR40","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/art.40753","volume":"71","author":"A Deodhar","year":"2019","unstructured":"Deodhar A, Poddubnyy D, Pacheco-Tena C, et al. Efficacy and safety of ixekizumab in the treatment of radiographic axial spondyloarthritis: sixteen-week results from a phase\u00a0III randomized, double-blind, placebo-controlled trial in patients with prior inadequate response to or intolerance of tumor necrosis factor inhibitors. Arthritis Rheumatol. 2019;71(4):599\u2013611.","journal-title":"Arthritis Rheumatol"},{"issue":"10217","key":"1323_CR41","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0140-6736(19)32971-X","volume":"395","author":"A Deodhar","year":"2020","unstructured":"Deodhar A, van der Heijde D, Gensler LS, et al. Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial. Lancet. 2020;395(10217):53\u201364.","journal-title":"Lancet"},{"issue":"8","key":"1323_CR42","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1136\/annrheumdis-2020-219717","volume":"80","author":"RB Landew\u00e9","year":"2021","unstructured":"Landew\u00e9 RB, Gensler LS, Poddubnyy D, et al. Continuing versus withdrawing ixekizumab treatment in patients with axial spondyloarthritis who achieved remission: efficacy and safety results from a placebo-controlled, randomised withdrawal study (COAST-Y). Ann Rheum Dis. 2021;80(8):1022\u201330.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"1323_CR43","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1007\/s13555-022-00743-9","volume":"12","author":"CE Griffiths","year":"2022","unstructured":"Griffiths CE, Gooderham M, Colombel J-F, et al. Safety of ixekizumab in adult patients with moderate-to-severe psoriasis: data from 17 clinical trials with over 18,000 patient-years of exposure. Dermatol Ther. 2022;12(6):1431\u201346.","journal-title":"Dermatol Ther"},{"issue":"1","key":"1323_CR44","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13075-019-1882-2","volume":"21","author":"A Deodhar","year":"2019","unstructured":"Deodhar A, Mease PJ, McInnes IB, et al. Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data. Arthritis Res Ther. 2019;21(1):111.","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"1323_CR45","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1093\/bjd\/ljad429","volume":"190","author":"KB Gordon","year":"2023","unstructured":"Gordon KB, Langley RG, Warren RB, et al. Bimekizumab safety in patients with moderate to severe plaque psoriasis: pooled data from up to three years of treatment in randomized phase\u00a03 trials. Br J Dermatol. 2023;190(4):477\u201385.","journal-title":"Br J Dermatol"},{"issue":"4","key":"1323_CR46","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1136\/ard-2022-223595","volume":"82","author":"D van der Heijde","year":"2023","unstructured":"van der Heijde D, Deodhar A, Baraliakos X, et al. Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase\u00a03 randomised controlled trials. Ann Rheum Dis. 2023;82(4):515\u201326.","journal-title":"Ann Rheum Dis"},{"key":"1323_CR47","volume":"102","author":"K Reich","year":"2022","unstructured":"Reich K, Tha\u00e7i D, Stingl G, et al. Safety of brodalumab in plaque psoriasis: integrated pooled data from five clinical trials. Acta Derm Venereol. 2022;102:adv00683.","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"1323_CR48","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/s12325-019-01145-8","volume":"37","author":"GR Burmester","year":"2020","unstructured":"Burmester GR, Gordon KB, Rosenbaum JT, et al. Long-term safety of adalimumab in 29,967 adult patients from global clinical trials across multiple indications: an updated analysis. Adv Ther. 2020;37(1):364\u201380.","journal-title":"Adv Ther"},{"issue":"6","key":"1323_CR49","first-page":"571","volume":"19","author":"KA Papp","year":"2020","unstructured":"Papp KA, Langholff W. Safety surveillance for ustekinumab and other psoriasis treatments from the Psoriasis Longitudinal Assessment and Registry (PSOLAR) Errata. J Drugs Dermatol. 2020;19(6):571\u20132.","journal-title":"J Drugs Dermatol"},{"issue":"8","key":"1323_CR50","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/RHU.0000000000000306","volume":"21","author":"L Li","year":"2015","unstructured":"Li L, Hagberg KW, Peng M, Shah K, Paris M, Jick S. Rates of cardiovascular disease and major adverse cardiovascular events in patients with psoriatic arthritis compared to patients without psoriatic arthritis. J Clin Rheumatol. 2015;21(8):405\u201310.","journal-title":"J Clin Rheumatol"},{"key":"1323_CR51","doi-asserted-by":"crossref","first-page":"1349636","DOI":"10.3389\/fimmu.2024.1349636","volume":"15","author":"L Ding","year":"2024","unstructured":"Ding L, Chen C, Yang Y, Zhang X. Major cardiovascular events under biologic psoriasis therapies: a 19-year real-world analysis of FAERS data. Front Immunol. 2024;15:1349636.","journal-title":"Front Immunol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01323-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-024-01323-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01323-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T22:31:20Z","timestamp":1738362680000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-024-01323-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["1323"],"URL":"https:\/\/doi.org\/10.1007\/s13555-024-01323-9","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"2 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Mark Lebwohl has received grants\/contracts from: Abbvie, Arcutis, Avotres, Boehringer Ingelheim, Cara therapeutics, Clexio, Dermavant Sciences, Eli Lilly and Company, Incyte, Inozyme, Janssen, Pfizer, Sanofi Regeneron, and UCB; has received honoraria as a consultant for: Almirall, AltruBio Inc., Apogee, Arcutis, AstraZeneca, Atomwise, Avotres Therapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Castle Biosciences, Celltrion, Corevitas, Dermavant Sciences, Dermsquared, Evommune, Facilitation of International Dermatology Education, Forte Biosciences, Galderma, Genentech, Incyte, LEO Pharma, Meiji Seika Pharma, Mindera, Pfizer, Sanofi Regeneron, Seanergy, Strata, Takeda, Trevi, and Verrica. Atul Deodhar has served as a consultant and\/or on the advisory board for: Bristol Myers Squibb, Eli Lilly and Company, Janssen, MoonLake, Novartis, Pfizer, and UCB Pharma; and has received research grants from: Bristol Myers Squibb, Celgene, Eli Lilly and Company, Janssen, Novartis, Pfizer, and UCB Pharma. Sergio Schwartzman has received grants and\/or contracts from: Eli Lilly and Company; serves on the National Psoriasis Foundation Medical Board; is part of the scientific advisory board at: Myriad Genetics; and is a consultant for: AbbVie, Eli Lilly and Company, Janssen, Jubilant Pharma, Myriad Genetics, Novartis, Regeneron, Sanofi, Stelexis Therapeutics, Teijin Pharma, and UCB Pharma. Carlo Salvarani has served as a consultant for: AbbVie, Eli Lilly and Company, and Roche; and has received grant\/research support from: Roche. Meghan Feely McDonald is associate staff at Mount Sinai Hospital, Mount Sinai West, and Mount Sinai Morningside; was an employee of Eli Lilly and Company\u00a0at the time of this manuscript development; has received consulting, travel, or speaker fees from: American Academy of Dermatology, Aerolase, Castle Biosciences, CeraVe\u2014L\u2019Or\u00e9al, DREAM USA, Galderma Aesthetics, Glow Recipe, La Roche-Posay\u2014L\u2019Or\u00e9al, Revian, Sonoma Pharmaceuticals, Sun Pharma, and Suneva Medical. Natalia Bello, Elsie L. Grace, Elsa Inman, Andris Kronbergs, and Marcus Ngantcha are employees and shareholders of Eli Lilly and Company. Proton Rahman has received grants\/contracts from: Janssen and Novartis; and has received honoraria as a consultant for: AbbVie, Eli Lilly and Company, Janssen, Novartis, and Pfizer. Kim A. Papp has served as a consultant, speaker, scientific officer, steering committee member, and\/or advisory board member for: AbbVie, Acelyrin, Akros, Alumis, Amgen, Arcutis, Bausch Health\/Valeant, Boehringer Ingelheim, Bristol Myers Squibb, Can-Fite Biopharma, Celltrion, Concert Pharmaceuticals, Dermavant, Dermira, DiCE Pharmaceuticals, DiCE Therapeutics, Evelo Biosciences, Forbion, Galderma, Horizon Therapeutics, Incyte, Janssen, Kymab, Kyowa Hakko Kirin, LEO, Lilly, Meiji Seika Pharma, Mitsubishi Pharma, Nimbus Therapeutics, Novartis, Pfizer, Reistone, Sanofi-Aventis\/Genzyme, Sandoz, Sun Pharma, Takeda, Tarsus Pharmaceuticals, UCB, and Zai Lab. Joseph F. Merola is a consultant and\/or investigator for: AbbVie, Amgen, Biogen, Bristol Myers Squibb, Dermavant, Eli Lilly and Company, Janssen, LEO Pharma, Novartis, Pfizer, Sanofi Regeneron, Sun Pharma, and UCB Pharma. Alice B. Gottlieb receives research\/educational grants from Highlights Therapeutics, Bristol Myers Squibb, Janssen, and UCB Pharma (all paid to Mount Sinai School of Medicine); she has received honoraria as an advisory board member and consultant for Amgen, AnaptypsBio, Avotres Therapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Dice Therapeutics, Eli Lilly and Company, Highlights Therapeutics, Janssen, Novartis, Sanofi, Teva, UCB Pharma, and Xbiotech (stock options for RA). Andrew Blauvelt has served as a speaker (received honoraria) for Eli Lilly and Company and UCB, has served as a scientific adviser (received honoraria) for AbbVie, Abcentra, Aclaris, Affibody, Aligos, Almirall, Alumis, Amgen, Anaptysbio, Apogee, Arcutis, Arena, Aslan, Athenex, Bluefin Biomedicine, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Celldex, Celltrion, CTI BioPharma, Dermavant, EcoR1, Eli Lilly and Company, Escient, Evelo, Evommune, Forte, Galderma, HighlightII Pharma, Incyte, InnoventBio, Janssen, Landos, Leo, Lipidio, Microbion, Merck, Monte Rosa Therapeutics, Nektar, Novartis, Oruka, Overtone Therapeutics, Paragon, Pfizer, Q32 Bio, Rani, Rapt, Regeneron, Sanofi Genzyme, Spherix Global Insights, Sun Pharma, Takeda, TLL Pharmaceutical, TrialSpark, UCB Pharma, Union, Ventyx, Vibliome, and Xencor, has acted as a clinical study investigator (institution has received clinical study funds) for AbbVie, Acelyrin, Allakos, Almirall, Alumis, Amgen, Arcutis, Athenex, Boehringer Ingelheim, Bristol Myers Squibb, Concert, Dermavant, DermBiont, Eli Lilly and Company, Evelo, Evommune, Galderma, Incyte, Janssen, Leo, Merck, Novartis, Pfizer, Regeneron, Sanofi, Sun Pharma, Takeda, UCB Pharma, and Ventyx, and owns stock in Lipidio and Oruka.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The protocols for all studies included in this analysis were approved by the ethics committee or institutional review board at each participating site. All studies were conducted in accordance with the ethical principles of the Declaration of Helsinki. Eligible patients provided written informed consent before initiating any study-related procedures.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}